HomeEXECUTIVESTamara Elias, M.D., Joins BehaVR, Inc. Board of Directors

Tamara Elias, M.D., Joins BehaVR, Inc. Board of Directors

February 9, 2021

Tamara Elias, M.D. has been appointed to the company’s board of directors as Independent Director.

Tamara Elias, M.D. currently serves as Vice President and Head of Global Partnerships & Innovation at Merck & Co., Inc.

Her expertise and experience will help guide BehaVR as it expands within behavioral health and works closely with health systems, payer organizations and biopharmaceutical leaders interested in this space.

“We are thrilled to have Dr. Elias join our team as our Independent Director. Her experience with clinical product development and commercialization and deep understanding of both the payer and life sciences sectors will be a huge asset to BehaVR as we continue to grow,” said Aaron Gani founder and CEO of BehaVR. “She has her finger on the pulse of the latest innovations and advancements in healthcare delivery, and we are excited for the perspective she will bring to our company as we expand our collaborations and develop new digital wellness and therapeutic solutions.”

“I am excited about the acceleration of digital wellness solutions to improve healthcare delivery, so look forward to working with the talented BehaVR team and distinguished Board to expand adoption of its vast capabilities,” said Elias. “I share the company’s commitment to helping people achieve their best health and welcome the opportunity to contribute to its efforts to achieve this important mission.”

Prior to joining Merck, Dr. Elias served as vice president of clinical product development at Aetna, vice president of corporate strategy and business development at Becton Dickinson, and a partner at Essex Woodlands Healthcare Partners, a healthcare-only growth equity firm. Earlier in her career, she was a management consultant at McKinsey, advising pharmaceutical, diagnostic and device companies in R&D, product commercialization and M&A.

Dr. Elias currently serves on the boards of medical device companies Avinger, Inc. and REVA Medical, and she has previously served on the boards of Millennium Pharmacy Systems, BreatheAmerica, Influence Health, and ATS Medical.

Tamara Elias, M.D. holds a Bachelor of Arts in Biology and Anthropology from Yale University and a Doctor of Medicine from The Johns Hopkins School of Medicine. She trained as a general surgeon at Massachusetts General Hospital.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy